WeVote
Log In

Bill

Bill

S 2294

Kay Hagan Tick Reauthorization Act

119th Congress Introduced by Susan Collins and 5 co-sponsors

The bill reauthorizes and expands federal funding for research, prevention, and awareness to combat tick-borne diseases like Lyme disease.

Introduced in Senate
0
WeVote Research Nonpartisan
Bill Summary · S 2294

Legislative bill overview

The Kay Hagan Tick Reauthorization Act (S 2294) is a legislative proposal aimed at reauthorizing and potentially expanding funding and efforts to combat tick-borne diseases. This bill is named in honor of Senator Kay Hagan, who was a strong advocate for addressing tick-borne illnesses such as Lyme disease. The legislation focuses on enhancing research, prevention, and public awareness initiatives related to tick-borne diseases, likely including provisions for federal agencies to coordinate their efforts more effectively and allocate resources toward studying and managing these diseases.

Why is this important

Tick-borne diseases, including Lyme disease, represent a significant public health challenge in the United States, with millions of cases reported annually and a growing geographic spread. Enhancing federal commitment and reauthorizing funding ensures continued research and development of improved diagnostic tools, treatments, and preventive strategies. The legislation helps elevate these diseases on the public health agenda and supports vulnerable populations affected by chronic tick-borne conditions.

Potential points of contention

  • Funding Allocation: Debate may arise over the sufficiency, source, and duration of funding provided for the reauthorization and expanded activities.
  • Scientific Priorities: Disagreement on the focus of research efforts, with some advocating for broader studies on multiple tick-borne diseases while others emphasize Lyme disease specifically.
  • Scope of Federal Involvement: Potential concerns about the federal government’s role versus state and local public health agencies in managing tick-borne disease initiatives.
  • Impact on Other Public Health Priorities: The bill may be scrutinized for diverting funds and attention from other infectious disease priorities within limited health budgets.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.